October 2019- Volume 15, Issue 10

In this Issue

Commentary

Optimized dosing: We can do better, but when?

Optimized dosing: We can do better, but when?

While we are increasingly able to make better drug choices for subpopulations thanks to companion diagnostics and more, actually optimizing dosing for an individual is an aspirational goal right now

Guest Commentary: The unique IP landscape of CRISPR/Cas9-edited animal models

Guest Commentary: The unique IP landscape of CRISPR/Cas9-edited animal models

An understanding of the patent history and intellectual property landscape surrounding the use of the CRISPR/Cas9 system is critical for any researcher considering designing a mouse or rat model using this technology

Clinical Trials

An influx of focus on wet AMD

An influx of focus on wet AMD

A trio of companies report trial progression or positive data for AMD-targeted therapeutics

Battling Batten disease

Battling Batten disease

Amicus gene therapy brings in positive interim results

Safety and statistical significance

Safety and statistical significance

Patients respond well to Aclaris’ ATI-501 in alopecia areata trial

Discovery

Getting to grips with chemoresistance

Getting to grips with chemoresistance

Scientists develop drug-resistant cell line for lymphoma to better model disease development and drug reactions

A path to prevent addiction?

A path to prevent addiction?

Scripps Research finds an anti-opioid pathway

AI answers

AI answers

Atomwise collaborates for drug development

Going GENTRL

Going GENTRL

Insilico Medicine has validated its new GENTRL AI system

Preclinical

Positive results for radiation prophylaxis

Positive results for radiation prophylaxis

Pluristem and the Department of Defense present positive PLX-R18 data

Healthy data for Cytokinetics' HCM candidate

Healthy data for Cytokinetics' HCM candidate

CK-274, which addresses hypercontractility in hypertrophic cardiomyopathy, reduces contractility in preclinical models

Rodents to the rescue

Rodents to the rescue

Taconic and ContraVir report positive preclinical tests for treating NASH

Research & Development

Brain vs. brain

Brain vs. brain

Brain organoids and brains of premature babies generate similar EEG patterns

Gut check

Gut check

French biotech company raises €6.2M for gut microbiome R&D

Teaming up on autoimmune disease

Teaming up on autoimmune disease

Exagen and University of Washington collaborate on lupus and rheumatoid arthritis research

Pushing against cancer

Pushing against cancer

Crescendo to collaborate with University of Oxford and University of Surrey

Pinpointing patients

Pinpointing patients

Researchers identify immune biomarker showing which HCC patients would benefit most from sorafenib

Contract Services

Making moves

Making moves

Sygnature Discovery moves U.S. base to Kendall Square

Diagnostics

T2 keeps trucking along

T2 keeps trucking along

Company’s direct-from-blood diagnostic tests post strong data, supporting multiple distribution agreements

A focus on FFPE

A focus on FFPE

Pressure BioSciences’ PCT platform lauded for its ability to process cancer biopsy samples

What’s the hubbub?

What’s the hubbub?

NUS, Agilent and NUH launch new translational R&D hub to boost clinical diagnostics

Scientists create a faster DNA testing method

Scientists create a faster DNA testing method

New ‘Vilnius-made’ method reportedly reduces DNA testing costs by 90 percent

AI-based blood testing

AI-based blood testing

Diagnostics detect cancer in dense breasts

Business & Government Policy

New campaign focuses on fighting superbugs

New campaign focuses on fighting superbugs

Working to Fight AMR aims to spur development of new antibiotics

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

Not passing the finish line

Not passing the finish line

Many pre-approved prescription drugs have not completed FDA approval process

Cannabidiol vs. epilepsy

Cannabidiol vs. epilepsy

NICE to work with GW Pharma on appraisals of cannabidiol

Editor's Focus

Editor’s Focus: An embarrassment of riches

Editor’s Focus: An embarrassment of riches

From a Focus Feature to Q&As, there's no shortage of bonus pieces in our October issue; no matter which indications interest you most, there's something for everyone
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2021 Issue Front Cover

Latest Issue  

• Volume 17 • Issue 11 • November 2021

November 2021

November 2021 Issue